Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN)
Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19
Sponsor: Instituto do Cancer do Estado de São Paulo
Terminated
futility analysis has demonstrated no difference between arms
Other terminated trials from Instituto do Cancer do Estado de São Paulo
- Adrenal Neoplasm · Phase NA · May 2023
- Plasmacytoma · Phase PHASE2 · Mar 2022
- Gastrointestinal Hemorrhage · Phase NA · Aug 2020
- Rectal Cancer · Phase NA · Apr 2020
- Solid Tumor · Phase PHASE2 · Sep 2019
See all terminations from Instituto do Cancer do Estado de São Paulo
Other COVID trials with similar outcome
Listed as NCT04447235, this PHASE2 trial focuses on COVID and Cancer and remains terminated or withdrawn. Sponsored by Instituto do Cancer do Estado de São Paulo, it has been updated 8 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Jul 2022 — Sep 2022 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jan 2021 — Jul 2022 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Instituto do Cancer do Estado de São Paulo
For direct contact, visit the study record on ClinicalTrials.gov .